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ABSTRACT
Objectives Rheumatic heart disease (RHD) is a major 
burden in low- income and middle- income countries 
(LMICs). Cardiac surgery is the only curative treatment. 
Little is known about patients with severe chronic 
RHD operated in LMICs, and challenges regarding 
postoperative follow- up are an important issue. At Tikur 
Anbessa Specialised Hospital, Addis Ababa, Ethiopia, we 
aimed to evaluate the course and 12- month outcome of 
patients with severe chronic RHD who received open- 
heart surgery, as compared with the natural course of 
controls waiting for surgery and undergoing only medical 
treatment.
Methods Clinical data and outcome measures were 
registered in 46 patients operated during five missions 
from March 2016 to November 2019, and compared 
with the first- year course in a cohort of 49 controls from 
the same hospital’s waiting list for surgery. Adverse 
events were death or complications such as stroke, other 
thromboembolic events, bleeding, hospitalisation for heart 
failure and infectious endocarditis.
Results Survival at 12 months was 89% and survival 
free from complications was 80% in the surgical group. 
Despite undergoing open- heart surgery, with its inherent 
risks, outcome measures of the surgical group were 
non- inferior to the natural course of the control group in 
the first year after inclusion on the waiting list (p≥0.45). 
All except six surgical patients were in New York Heart 
Association class I after 12 months and 84% had resumed 
working.
Conclusions Cardiac surgery for severe chronic RHD is 
feasible in LMICs if the service is structured and planned. 
Rates of survival and survival free from complications 
were similar to those of controls at 12 months. Functional 
level and resumption of work were high in the surgical 
group. Whether the patients who underwent cardiac 
surgery will have better long- term prognosis, in line with 
what is known in high- income countries, needs to be 
evaluated in future studies.
INTRODUCTION
Rheumatic heart disease (RHD) is globally 
a major cause of morbidity and mortality. 
Despite its near non- existence in the native 
population of the Western world, RHD is 
frequent in low- income and middle- income 
countries (LMICs). The Global Burden of 
Disease Study estimates that acute rheumatic 
fever (ARF) and subsequent (RHD) affect 
33.4 million people worldwide, and it is esti-
mated that the annual number of deaths 
due to RHD exceeds 300 000.1 Penicillin 
Key questions
What is already known about this subject?
 ► Rheumatic heart disease (RHD) is a major cause of 
mortality and morbidity in low- income and middle- 
income countries (LMICs). In high- income countries, 
cardiac surgery is well established and recommend-
ed in severe RHD. There is limited availability of car-
diac surgery and postoperative follow- up capacity 
in most LMICs, and knowledge about outcome after 
surgery in such settings is sparse.
What does this study add?
 ► Cardiac surgery and postoperative follow- up within 
an educational programme are feasible in an LMIC 
setting and the short- term outcome is acceptable.
How might this impact on clinical practice?
 ► Increased awareness of RHD as a major health 
problem in LMICs highlights the necessity of es-
tablishing programmes of cardiac surgery and 
postoperative follow- up. The involvement of skilled 
cardiac teams in establishing cardiac surgery pro-
grammes in LMICs may improve therapy for a large 
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treatment of patients with RHD may reduce new episodes 
of ARF and thus postpone disease progression.2 3 Once 
severe RHD is present, medical therapy has no curative 
effect, leaving the patient with the option of surgery or 
inevitable death.4–6 Thus, establishing cardiac surgery for 
severe RHD in LIMCs has become an important issue.3 7–11 
Even though RHD used to also be frequent in the Western 
world and cardiac surgery became the recommended 
treatment for advanced disease,12–16 the literature on 
such treatment in LMICs is scarce and includes limited 
follow- up data.3 17–21 For the same reasons, the natural 
course of severe RHD treated with modern medication 
is uncertain.17 22–25 In this study, we aimed to evaluate the 
perioperative course during open- heart surgery and at 12 
months’ follow- up in patients with severe chronic valvular 
RHD, in an ongoing bilateral educational programme 
between Haukeland University Hospital, Norway, and 
Tikur Anbessa Specialised Hospital, Addis Ababa, Ethi-
opia. The primary purpose of our mission was to build a 
public cardiac surgery service in an LMIC institution with 
a planned framework that includes all necessary types of 
medical specialists in the heart team (box 1). Second, 
we aimed to provide high- quality open- heart surgery in 
chronic RHD patients and to maintain sustainability by 
establishing an educational programme with involvement 
of local medical professionals over a period of 10 years. 
Lastly, as presented in this study, we aimed to compare 
the surgical results with the course of a retrospective 
control group with similar characteristics and on medical 
therapy, who were on the same hospital’s waiting list of 
patients due to the limited cardiac surgery service. The 
main hypothesis was that a structured and planned open- 
heart surgery service for severe chronic RHD was feasible 
in this LMIC hospital and could provide acceptable short- 
term outcomes.
METHODS
Study design and population
The study was observational in design, with detailed 
description of outcomes from the surgically treated 
patients and comparison with similar patients who were 
on medical therapy due to the absence of a cardiac surgery 
service. From the local RHD waiting list for open- heart 
surgery or percutaneous balloon valvuloplasty (PTMV), 
consisting of approximately 6000 patients, 88 were 
selected by the local staff for surgical screening by the 
Norwegian heart team during five missions from March 
2016 to November 2019. Criteria for patient selection was 
long time on the waiting list for surgery, being considered 
eligible for intervention and compliant to follow- up. The 
surgical team had extensive experience in heart valve 
surgery of all kinds, including valve repair. The heart team 
chose the operative treatment, based on valve pathology, 
compliance with anticoagulation treatment and comor-
bidity, as well as family planning and rural housing issues. 
Of the screened 88 patients, 42 were excluded from or 
postponed for surgery, as shown in figure 1. Thus, 46 
patients with RHD underwent cardiac surgery and were 
included in the surgical group for further analyses. No 
patient was included or excluded on the basis of socio-
economic background. From the same waiting list, 157 
control patients on medical therapy were included based 
on similar characteristics for disease severity, age and sex 
at the time of placement on the waiting list. From this 
group, 14 underwent valvular surgery or PTMV by other 
missions or abroad and 94 were lost to follow- up; thus, the 
control group finally consisted of 49 patients (figure 1).
Data collection
Data were collected by the heart team at screening and 
by Norwegian and local health professionals during 
follow- up. Anthropometric and blood pressure measure-
ments were part of the clinical examinations. Body surface 
area (BSA) was calculated by the Mosteller formula. 
A 12- lead ECG was recorded for assessment of arrhyth-
mias. Serum creatinine and other blood samples were 
collected during screening and analysed at the hospital 
laboratory. At follow- up, analyses were performed at 
Arsho Medical Laboratory, a certified private laboratory 
in Addis Ababa. International normalised ratio (INR) was 
Box 1 Overview of medical personnel provided for surgical 
service and education at black lion Hospital, Addis Ababa.
Types of medical professionals in the Norwegian heart 
team:
Cardiac surgeon










Figure 1 Flow chart of the study population. PTMV, 
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measured using a hand- held CoaguCheck Pro II (Roche 
Diagnostics, Basel, Switzerland). The use of antibiotics, 
anticoagulation, diuretics, beta- blocker, ACE inhibitors 
and digoxin were registered. Heart failure symptoms 
were classified according to the New York Heart Asso-
ciation (NYHA) guidelines.26 At baseline, heart failure 
was defined by the following criteria: NYHA class ≥II, 
structural heart disease and at least one of the following: 
(1) at least two heart failure medications (furosemide, 
spironolactone, beta- blocker, ACE- inhibitor, digoxin); 
(2) left ventricular ejection fraction (LVEF) <50%; (3) 
peak tricuspid regurgitant velocity ≥3 m/s; (4) pleural 
effusion or ascites and (5) history of hospitalisation for 
heart failure. The EuroSCORE II calculator was used to 
assess risk for surgical patients.27
Echocardiography
Echocardiography was performed by cardiologists from 
the Norwegian heart team and a local cardiologist in 
the surgical group and by local cardiologists only in the 
controls. In both groups, LVEF and volumes were calcu-
lated from apical four- chamber and two- chamber views 
(A4C and A2C) using the Simpson method. Tricuspid 
annular plane systolic excursion (TAPSE) was measured 
in right ventricular focused views by reconstructed motion 
mode. Similarly, systolic pulmonary artery pressure 
(SPAP) was calculated using the peak gradient across the 
tricuspid regurgitation using continuous Doppler (CW) 
in A4C, plus the right atrial pressure estimated from the 
size and respiratory variation of the inferior vena cava.28 
LV stroke volume indexed for BSA and cardiac index was 
calculated using Doppler measurements. The severity of 
the rheumatic effect on the mitral valve was calculated 
using the Wilkins score.29 Grading of mitral stenosis (MS) 
was based on the valve area calculated using planimetry in 
parasternal short- axis views and/or by the pressure half- 
time of the mitral inflow Doppler spectrum (mitral valve 
area=220/pressure half- time).30 Grading of the severity 
of mitral regurgitation (MR) was based on valvular 
morphology, regurgitant jet flow colour and semiquanti-
tative measurements such as vena contracta and signs of 
systolic pulmonary vein flow reversal. In addition, quanti-
fication of the regurgitant volume by proximal isovelocity 
hemispheric surface area was done in the surgical group. 
The grading of the severity of all valvular stenoses or 
regurgitations was done according to guidelines.31 32 All 
echocardiographic recordings were acquired using a GE 
Vivid E9 or a Vivid i ultrasound scanner (GE Ultrasound, 
Horten, Norway). All echocardiographic analyses of the 
surgical patients presented here were done offline using 
Echopac SWO, v. 201–203 (GE Ultrasound).
Perioperative treatment, follow-up and outcome measures
Open- heart surgery with median sternotomy was 
performed using general anaesthesia and cardiopulmo-
nary bypass circulation. All patients received perioper-
ative evaluation by transoesophageal echo. All patients 
had a temporary pacemaker implanted during surgery; a 
permanent pacemaker (Medtronic) was later implanted 
if indicated by sustained postoperative conduction block. 
Patients with implanted mechanical valves or other indi-
cations for anticoagulation were treated with oral warfarin 
in accordance with international guidelines.31 Target 
INR for patients with mechanical aortic valve only, was 
2.5 (range 2.0–3.0). For patients with a mechanical mitral 
valve (including those with more than one mechanical 
valve) target INR was 3.0 (range 2.5–3.5). Additional 
aspirin was not routinely used. Before postoperative 
discharge, all patients were evaluated with transthoracic 
echocardiography, laboratory testing and clinical evalu-
ation. Regular follow- up was carried out at the hospital 
outpatient cardiac clinic. All patients were scheduled for 
evaluation after 6 and 12 months by a team consisting 
of local and Norwegian cardiologists and examined with 
comprehensive echocardiography, physical examination, 
12- lead ECG, and laboratory testing. Optimised warfarin 
treatment was given special attention. For logistic reasons 
(ie, the ongoing pandemic), 16 patients did not get echo-
cardiographic follow- up at exactly 12 months, but later 
on.
The perioperative outcome measures were mortality, 
need for permanent pacemaker, need for pericardial 
drainage, internal bleeding of any kind and thromboem-
bolic events such as stroke or peripheral emboli. Events 
occurring within the first 30 days after surgery were clas-
sified as early postoperative complications. At 12 months, 
additional outcome measures were new onset of atrial 
fibrillation, infective endocarditis, valvular thrombosis 
and heart failure hospitalisation. The first occurrence 
of any postoperative event was used for outcomes in 
the surgical group. Similarly, the first occurrence of any 
event after inclusion on the waiting list was used in the 
control group. NYHA class and resumption of profes-
sional activity for surgical patients were also registered. 
Outcome measures of the control group were collected 
by searches of electronic and printed medical reports, as 
well as outpatients’ visits and telephone calls.
End points were defined as follows: Atrial fibrillation, 
as diagnosed by ECG. Stroke was defined as physician- 
confirmed sudden onset of neurological deficit consis-
tent with ischaemia of a cerebral vascular territory, lasting 
≥24 hours, with or without neuroimaging evidence. 
Peripheral embolic episode was diagnosed clinically by 
loss of arterial pulse and clinical signs of end- organ isch-
aemia (ie, ischaemic limb pain or gangrene). If cardiac 
or prosthetic heart valve thrombosis was suspected by 
transthoracic echocardiography, supplementary tran-
soesophageal examination and/or fluoroscopy was used 
to confirm the diagnosis. Bleeding event was defined 
as symptoms and/or findings consistent with internal 
bleeding, without specified drop in haemoglobin. Infec-
tive endocarditis was defined according to the modified 
Duke criteria.33 Heart failure admissions were defined 
by hospital readmission with clinical diagnosis of heart 
failure, even if natriuretic peptides or echocardiograms 







ber 11, 2021 at H












4 Hauge SW, et al. Open Heart 2021;8:e001706. doi:10.1136/openhrt-2021-001706
was defined by a 100% return to work or if the patient 
had resumed their studies.
Statistical analyses
Continuous variables are expressed as mean and SD or 
as median and IQR, as appropriate. Normality was eval-
uated using histograms and normality plots. Categor-
ical variables are presented as frequencies and propor-
tions. The Student’s t- test and Wilcoxon test were used 
for comparisons of groups or sexes when appropriate. 
Proportions were compared using the χ2 test and Fish-
er’s exact test. Survival analyses were performed using the 
Kaplan- Meier method. The starting point for inclusion in 
the study was defined as the date of open- heart surgery 
for the surgical group and the date of inclusion on the 
open- heart surgery waiting list for controls. No missing 
data were imputed.
In case no event had occurred, patients and controls 
were censored at 12 months from surgery or inclusion 
on the waiting list, respectively. Values of p<0.05 were 
considered statistically significant. All statistical analyses 
were performed using IBM SPSS Statistics V.26.
RESULTS
Population and surgery
The baseline characteristics of the 46 surgical patients 
and 49 controls are shown in table 1. Both groups had 
characteristics of symptomatic severe RHD. The controls 
were approximately 4 years younger, with a mean age of 
26 years as compared with 30 years in the surgical group 
(p=0.04). Females were overrepresented in both groups 
(65% of the surgical group and 76% of the controls). 
In the surgical group, height, weight, and BSA differed 
between sexes, but BMI was similar. The surgical patients 
had been symptomatic for a median of 7 years longer 
before inclusion in the study (time of surgery) compared 
with controls (enrolled at the time of inclusion on the 
waiting list) (p<0.01). The surgical group had more 
advanced disease than the control group, with higher 
proportions of patients with atrial fibrillation (p<0.01), 
use of anticoagulation (p<0.01) and use of beta- blocker 
(p<0.01), respectively. Furthermore, more patients in the 
surgery group had experienced thromboembolic events 
compared with the controls. EuroSCORE II was higher 
for women than for men, at 3.3% and 1.6%, respectively.
Echocardiography
Detailed echocardiographic data for the surgical group 
are summarised in table 2. Mitral valve disease was the 
most common valve defect, with severe MS (≤1.5 cm2) in 
62% and critical MS (≤1.0 cm2) in 35%. Furthermore, 62% 
had moderate or severe MR, and 28% had combined MS 
and MR. The average Wilkins score was high (11). LVEF 
was within normal range (mean 56%), whereas median 
cardiac index and indexed LV stroke volume were low 
(2.2 L/min/m2 and 28 mL/m2, respectively). SPAP was 
elevated, with a mean of 56 mm Hg.
Details of concomitant surgical procedures are shown 
in table 3. Most patients needed multiple heart surgery 
procedures, with means of 1.8 valvular and 2.4 total 










Female, n (%) 30 (65) 37 (76) 0.27
Age, mean (SD), years* 30.0 (8.6) 25.9 (9.9) 0.04
NYHA class III–IV, n/a (%). 21/46 (46) 21/37 (57) 0.30
Height, mean (SD), cm* 162 (9.5) –
Weight, mean (SD) kg* 57.3 (13.1) –
Body mass index, mean 
(SD), kg/m2†
21.8 (4.3) –
Body surface area, mean 
(SD), m† *
1.59 (0.20) –
Blood pressure systolic, 
mean (SD), mm Hg
117 (21) 107 (15) <0.05
Blood pressure diastolic, 
mean (SD), mm Hg
73 (11) 66 (12) <0.05
Heart rate, median (IQR), 
per minute
80 (74–90) 80 (78–92) 0.17
Serum creatinine, mean 
(SD) mg/dL
0.93 (0.25) –
Time on waiting list/
symptoms, median (IQR), 
years†
10 (6–15) 3 (1–5) <0.01
Antibiotics n/a (%) 40/46 (87) –
Anticoagulation, n/a (%) 26/46 (57) 6/42 (14) <0.01
Beta- blocker, n/a (%) 19/46 (41) 6/49 (12) <0.01
Diuretics, n/a (%) 35/46 (76) 34/48 (71) 0.56
Left ventricular ejection 
fraction ≤50, n/a (%)
10/43 (23) 3/36 (8) 0.08
Peak systolic artery 
pressure ≥60, n/a (%), 
mm Hg
20/43 (47) 10/15 (67) 0.18
Numbers of valves 
affected, mean (SD)
1.8 (0.7) 1.7 (0.7) 0.66
EuroSCORE II (%)* 2.7 (1.7) –
Complications of RHD:
Atrial fibrillation, n/a (%) 23/46 (50) 7/39 (18) <0.01
Thromboembolic disease, 
n/a (%)‡
6/46 (13) 0/41 (0) 0.02
Stroke, n/a (%) 2/46 (4) 0/41 (0) 0.18
Infective endocarditis, 
n/a (%)*
2/46 (4) 2/41 (5) 0.91
Heart failure, n/a (%)§ 36/46 (78) 36/49 (74) 0.59
*Sex differences in the surgery group: age, women 28.1 versus men 33.6 
years; height, women 156.7 vs men 171.4 cm; weight, women 53.5 vs men 
64.3 kg; BSA, women 1.52 vs men 1.75 m2; infective endocarditis, women 0% 
versus men 13%; EuroSCORE II, women 3.3 vs men 1.6.
†For surgical patients: years of symptoms before surgery; for controls: years 
of symptoms before inclusion on the waiting list.
‡Thromboembolic disease: peripheral emboli, left atrial thrombus and valve 
thrombus.
§Heart failure: NYHA ≥2, structural heart disease and at least one of the 
following: >2 heart failure medicines, EF <50, TR v/max >3 m/s, pleural 
effusion/ascites, admissions with heart failure.
BSA, body surface area; EF, ejection fraction; n, numbers; n/a, numbers/
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procedures performed per patient. The mitral valve 
was the most commonly diseased valve (93%). Mechan-
ical valve implantation was the most common valvular 
procedure. Similarly, tricuspid valve repair was the most 
common valvular reconstruction accounting for more 
than half of the total, whereas mitral and aortic valve 
repair were performed in 7 (15%) and 2 (4%), respec-
tively. Surgical repair procedures included annuloplasty, 
commissurotomy, leaflet extension and subvalvular 
procedures.
Early outcomes
Three patients died within the first 30 days, including 
one due to severe pulmonary hypertension refractory to 
medication. Another patient who initially was well mobi-
lised died following in- hospital cardiac arrest. Low serum 
potassium level was confirmed in this patient. The third 
early death occurred after re- admittance for septicaemia 
of unknown origin and accompanying diarrhoea 23 days 
after surgery.
Five (11%) patients, all of whom had multi- valvular 
surgery, including four with tricuspid valve repair, devel-
oped complete atrioventricular conduction block after 
surgery and received permanent pacemaker implan-
tation. Of the latter, two had atrial fibrillation prior to 
surgery. Furthermore, one patient (2%) needed percu-
taneous pericardial drainage early postoperatively. Two 
patients (4%) suffering from perioperative stroke recov-
ered with minimal sequelae.
One-year outcomes
Five (11%) of the surgical patients died within the first 
12 months. Of the subsequent deaths, one patient died 
suddenly at home 64 days after surgery without any 
prior symptoms; ventricular arrhythmia was therefore 
suspected. The last death was a sudden cardiac arrest 
10 months after surgery. The female patient was first 
admitted with excessive pericardial effusion due to post- 
pericardiotomy syndrome, which was successfully treated 
with a pericardial window to the left chest at 6 months 
follow- up, and she was discharged in good shape. She died 
suddenly 4 months later, probably due to arrhythmia, as 
she was given a combination of digoxin and diuretics with 
poor local medical follow- up.
Additional outcomes at 12 months postsurgery were 
admissions for heart failure in two patients. No surgical 
patient developed prosthetic valve dysfunction or suffered 
from infectious endocarditis, thromboembolism or major 
bleeding during the follow- up. Two surgical patients 
(6%) had new onset of atrial fibrillation, whereas two 
patients with atrial fibrillation at baseline had regained 
sinus rhythm at the 12 month follow- up.
Five control patients (10%) died during the first 12 
months of follow- up and two were readmitted with heart 
failure. The survival rates at 12 months were 89% in the 
surgical group and 90% in the controls, with no differ-
ence between groups (figure 2). Survival free of compli-
cations was 80% in the surgical group and 86% in the 
Table 2 Echocardiographic measurements from the surgical group
Variable N available Mean (95% CI)
Left ventricular dimension, end- diastolic, mm 45 53 (50 to 56)
Left ventricular ejection fraction, % 46 56 (53 to 58)
Left ventricular end- diastolic volume, mL 38 126 (106 to 147)
Indexed left ventricular stroke volume, median (IQR), mL/m2. 34 28 (22 to 43)
Cardiac index, median (IQR), L/min/m2 34 2.2 (1.8 to 4.2)
Indexed left atrial volume, median (IQR), mL/m2 38 102 (71 to 186)
Tricuspid annular plane systolic excursion, mm 44 20 (18 to 21)
Systolic pulmonary arterial pressure, mm Hg 41 56 (50 to 62)
Severe mitral stenosis*, n (%) 46 28 (62)
Very severe mitral stenosis†, n (%) 46 16 (35)
Mean gradient mitral valve‡, mm Hg 28 13 (11 to 15)
Mitral valve area§, cm2 27 0.99 (0.87 to 1.12)
Moderate to severe mitral regurgitation, n (%) 46 28 (61)
PISA mitral regurgitation volume¶, mL 14 71 (54 to 88)
Wilkins score** 37 11 (10 to 12)
Moderate to severe aortic stenosis and/or aortic regurgitation, n (%) 46 14 (30)
Moderate to severe tricuspid stenosis and/or tricuspid regurgitation, n (%) 46 25 (54)
Values are mean (95% CI) if not otherwise specified.
*Mitral valve area <1.5 cm2.
†Mitral valve area <1.0 cm2.
‡Mean gradient given for patients with severe mitral stenosis.
§Mitral valve area given for patients with severe mitral stenosis.
¶Regurgitant volume by PISA, given for patients with mod- severe mitral regurgitation.
**Wilkins score given for patients with rheumatic mitral disease.
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Table 3 Surgical data and complications during the 30- day postoperative period
Specification Total (n=46) Women (n=30) Men (n=16) P value sex difference
Extracorporeal circulation time, mean (SD), min 151 (46) 148 (41) 157 (56) 0.57
Aortic cross clamp time, mean (SD), min 111 (39) 109 (38) 117 (43) 0.48
Procedures per patient, mean (SD)* 2.4 (1.0) 2.6 (0.8) 2.1 (1.3) 0.15
Valve procedures per patient, mean (SD) 1.8 (0.7) 1.9 (0.6) 1.6 (0.7) 0.10
Aortic valve procedures, n 14 7 7
  Replacement; mechanical prosthesis, n (%) 12 (26) 5 (17) 7 (44) <0.05
  Aortic valve repair, n (%) 2 (4) 2 (7) 0 (0) 0.29
Mitral valve procedures, n 43 30 13
  Replacement; mechanical prosthesis, n (%) 35 (76) 24 (80) 11 (67) 0.33
  Replacement; biological prosthesis, n (%) 1 (2) 0 (0) 1 (6) 0.33
  Mitral valve repair, n total (%), (ring-








Tricuspid valve procedures, n 25 20 5
  Replacement; biological prosthesis, n (%) 1 (2) 0 (0) 1 (6) 0.16







Complications perioperatively and postoperatively
Mortality <30 days, n (%) 3 (7) 3 (10) 0 (0) 0.19
Permanent pacemaker implantation, n (%) 5 (11) 4 (13) 1 (6) 0.46
Pericardial drainage, n (%) 1 (2) 1 (3) 0 (0) 0.46
Stroke, n (%) 2 (4) 1 (3) 1 (6) 0.64
*Including valvular procedures and others such as left atrial appendage closure, left atrial thrombectomy, atrial septal defect closure 
secondary to failed balloon angioplasty, etc.
†Subvalvular procedures (one with debridement of subvalvular abscess; the others all include transition of chordae, placement of 
neochordae and cleavage of subvalvular apparatus).
‡Ring plasty, commissurotomy and subvalvular procedures.
Figure 2 Survival at 12- month follow- up. Surgical group 
(blue) and the control group (red). Participants without events 
are censored at 365 days.
Figure 3 Survival free from complications at 12- month 
follow- up. The surgical group (blue) and the cohort of 
historical controls (red). All participants without events are 
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controls, with no significant difference (figure 3). Impor-
tantly, no surgical or control patient was lost to follow- up. 
All patients except six (85%) were in NYHA class I at 12 
months following surgery, and 84% of the patients had 
returned to their professional activity. Tables 3 and 4 
show the favourable outcomes at the 12- month follow- up 
postsurgery.
DISCUSSION
The study presents current information on short- term 
outcome following open- heart surgery for severe chronic 
RHD and the natural history of conservatively treated RHD 
in LMICs. Despite a number of challenging medical and 
logistic factors, cardiac surgery for severe long- standing 
RHD is feasible in such environments if the programme 
is well structured and planned. Furthermore, all surgery 
and follow- up were part of an educational programme 
that aims to create a sustainable framework for a recently 
established cardiac service. Both survival and survival 
free of complications at 12 months were equal to those 
of patients with similar characteristics getting medication 
only. Important for comparison of the two groups is the 
more advanced clinical status of the operated group, as 
the surgical patients were included after a median 10 
years on the waiting list, while the natural course of the 
controls reflects the first year after referral. If proper 
follow- up is maintained, it is expected that patients who 
have been successfully operated will do better in the long 
term as compared with patients receiving conservative 
treatment.5 6
Population
As a randomised study and propensity matching would 
be unrealistic, the characteristics of the two groups were 
balanced with respect to sex and severity of valvular disease 
at the time of inclusion on the waiting list. However, 
the control group was younger, as follow- up started at 
inclusion on the waiting list compared with the date of 
surgery in the intervention group. As 94 (60%) of the 
eligible controls were excluded due to missing data, the 
distribution of sex and disease severity differed somewhat 
between the surgical patients and the controls, with more 
female patients in the control group and more severe 
disease and comorbidities in the surgical patients. Thus, 
the controls reflect the natural course of the disease itself.
The medical treatment differed between the groups. 
Whether the observations of less atrial fibrillation, less 
use of anticoagulation and fewer thromboembolic events 
among the controls are related to younger age and shorter 
time since referral or less comprehensive assessment is 
uncertain. In line with previous studies, we present a 
population of predominantly females of young age with 
severe rheumatic valvular disease. Compared with a recent 
publication, this population had more long- standing and 
severe symptoms, and congestive heart failure was more 
common.4 For surgical patients, SPAP was significantly 
elevated (mean 56 mm Hg) and 24 (52%) had reduced 
RV function (TAPSE <20 mm). Even though LVEF was 
>50% in 33 (77%) of the patients, median indexed stroke 
volume was only 28 mL/m2, which indicates poor LV 
function in a large proportion of the patients. Together 
with the young age of the population, this indicates that 
the relatively low EuroSCORE II in the population prob-
ably does not truly reflect the surgical risk, an opinion in 
accord with previous reports.34
Outcomes
Follow- up data after cardiac surgery for severe chronic 
RHD in LMICs is sparse. The observational design and 
inherent differences between the groups indicate that 
comparisons between the groups should be interpreted 
with caution. The mortality rate and survival free from 
complications within 12 months after surgery were 
comparable to the natural course of symptomatic RHD 
patients with similar characteristics. However, there were 
great differences in the grade of RHD and symptom 
duration between the groups, which were in favour of 
the control group within 12 months’ follow- up. The early 
postoperative deaths may be attributed to the setting in 
which local experience and resources were scarce. Some 
of these deaths would probably be avoided in societies 
with optimal medical follow- up programmes and enough 
resources.
Our survival rates after cardiac surgery in LMICs are in 
line with others, but in numerous previous reports a large 
proportion of the patients were lost to follow- up, even 
during the first year, and the mortality rates might have 
been underestimated as a result.18 20 21 35 Thus, a strength 
of this study is the complete follow- up of all surgical 
patients. The outcome for the control group is also in 
line with those of previous publications.4 24 However, a 
substantial proportion of patients eligible as controls were 
excluded after further analysis, as data were missing that 
could not be updated even after several attempts. Thus, 
we also believe that studies of control groups of patients 










NYHA 1 at 12 
months, n (%)
35 (85) –





Mortality, n (%) 5 (11) 5 (10) 0.90
Stroke, n (%) 2 (5) 0 (0) 0.13
Heart failure 
hospitalisation, n (%)
2 (5) 2 (5) 0.94
New onset AFIB, 
n/a (%)*
2/32 (6) –
No patients experienced IE, other thromboembolic events or bleedings.
*Missing data on nine patients in the surgical group.
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with severe chronic RHD on medical therapy generally 
underestimate mortality and severe complications.
Among the main concerns following implantation of 
mechanical valves were complications related to antico-
agulation therapy and pregnancy. We did not see any 
complications from anticoagulation or pregnancy during 
12 months’ follow- up, although comprehensive informa-
tion and scrutiny were given to reveal bleeding complica-
tions and prosthetic valve dysfunction. Female patients 
were advised not to become pregnant in the first year after 
surgery. The establishment of an INR clinic especially 
for the surgical patients, organised by a local pharmacist 
and supported by local physicians, played an important 
role in proper INR monitoring and it enhanced patient 
awareness about this critical issue.
The present study was encouraging concerning the 
clinical effects of cardiac surgery on cardiac symptoms 
and functional improvement in RHD patients. Impor-
tantly, surgical patients experienced far fewer symptoms 
postoperatively, in line with previous findings,35 and most 
resumed professional activity.
Ethical considerations
A randomised controlled study would not be ethically 
acceptable. As cardiac surgery service was unavailable 
to a large group of patients in need of surgery, we were 
able to construct a control group that added informa-
tion regarding the natural history of advanced RHD in 
the LMIC setting. Partly based on ethical considerations, 
patients with the most severe disease but still assessed as 
operable by the heart team were prioritised for surgery. 
In some cases, the patients were technically operable, 
but declined surgery as they carried too high a surgical 
risk due to severe heart failure, critical pulmonary hyper-
tension or severe sequelae following previous stroke 
from cerebral embolisation. These categories of patients 
would have to undergo preoperative optimised medical 
treatment or would require robust intensive care facilities 
and postoperative rehabilitation programmes currently 
unavailable in LMICs. Patients screened by the heart 
team but not accepted for operation were not included 
as controls.
Limitations
The main limitation is the low number of participants and 
controls. However, none of the included patients was lost 
to follow- up, which is uncommon in studies originating 
from LMICs. The design is observational, and compari-
sons between the surgical and control group should be 
interpreted with caution as they are not equal groups. 
The surgical patients were symptomatic for a longer time, 
even though they had similar characteristics at the time 
of their inclusion on the waiting list. We lack comprehen-
sive data on comorbidity and some outcome data in the 
control group. Despite this, our findings add to existing 
knowledge concerning outcomes for surgical RHD 
patients in LMICs. The global coronavirus pandemic has 
influenced the number of surgeries and their follow- up 
and may have also worsened the outcome in some of the 
patients, as this most unfortunate event is an extraburden 
on healthcare systems, especially in LMICs.
CONCLUSION
Outcome within 12 months after open- heart surgery 
for severe chronic RHD in a sub- Saharan country was 
acceptable as compared with the natural history of RHD 
in a control group with shorter disease duration. Most 
patients improved to NYHA class I and resumed profes-
sional activity. With a proper selection of patients and 
a structured team approach, surgery with acceptable 
short- term results for this group of patients is achievable. 
Careful cardiac follow- up and adequate anticoagulation 
is mandatory. Evaluation of long- term outcomes is impor-
tant for future treatment of this large group of young 
individuals with severe RHD in LMICs.
Author affiliations
1Department of Circulation and Medical Imaging, Norwegian University of Science 
and Technology, Trondheim, Norway
2Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
3Clinic of Cardiology, St Olavs University Hospital, Trondheim, Norway
4Department of Medicine, Levanger Hospital, Levanger, Norway
5Department of Cardiology, Oslo University Hospital, Oslo, Norway
6Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, 
Hordaland, Norway
7Department of Cardiology, School of Medicine, Addis Ababa University College of 
Health Sciences, Addis Ababa, Oromia, Ethiopia
8Department of Surgery, School of Medicine, Addis Ababa University College of 
Health Sciences, Addis Ababa, Oromia, Ethiopia
9Department of Surgical Services, Haukeland University Hospital, Bergen, Norway
10Clinic of Cardiology, Linköping University Hospital, Linköping, Sweden
Contributors SWH is the main author of the article and have been in charge of 
organising the follow- up, collecting the data, analysing the data and designing 
the work. RH is the head cardiothoracic surgeon and in charge of the project 
'Cardiac surgery and cardiology in Ethiopia' as a whole, and has been participating 
in all parts of the work, he is one of the main supervisors. HD and MEE are the 
main cardiologist in the project 'Cardiac surgery and cardiology in Ethiopia' and 
has been participating in all parts of the work, they are both main supervisors of 
the work. RMP and AS are cardiothoracic surgeons in the project and has been 
especially important in the acquisition of the pre and perioperative data, as well 
as substantial contributions elsewhere. NB and TG are cardiologist in the project 
and been essential in acquiring echocardiographic and follow up data. MF and 
HKB are anaesthetists in the project and have been important in the peri and 
postoperative course in the operated patients, with important contributions in all 
aspects of the project. N- EN is an interventional cardiologist who has important 
inputs in the selection and treatment of the operated patients. KV is the head of 
the cardiac department in Haukeland university hospital and have been essential 
in planning and facilitating the project as a whole, as well as important scientific 
contributions. DM and SA are Ethiopian cardiologists that have been essential for 
the clinical project as well as important in the scientific work, especially in the 
follow- up of the control group. BN is the head of cardiothoracic surgery at Tikur 
Anbessa Spesialised Hospital and has been the main person organising the clinical 
and scientific work locally, and made substantial contributions in both fields. All 
authors have been involved in the novel project, 'Cardiac surgery and cardiology 
in Ethiopia' during the last 5 years, participating actively in clinical and scientific 
activity during 2 planning missions and 7 clinical and research missions. All authors 
have made substantial contributions to the conception or design of the work, the 
acquisition, analysis and interpretation of data for the work. All authors have been 
involved drafting the work or revising it critically for important intellectual content. 
All authors have madefinal approval of the version to be published. All authors have 
agreed to be accountable for all aspects of the work in ensuring that questions 








ber 11, 2021 at H











9Hauge SW, et al. Open Heart 2021;8:e001706. doi:10.1136/openhrt-2021-001706
Cardiac surgery
Funding This work was funded by grants from Haukeland University Hospital, the 
Norwegian University of Science and Technology, and the Mohn family, Bergen, 
Norway. The industrial companies Edwards Medical, Abbott, and Medtronic have 
contributed heart valves and pacemakers used in this project. Personnel salaries 
were given on an ordinary basis by Tikur Anbessa Specialised Hospital, Haukeland 
University Hospital, Oslo University Hospital, and the Norwegian University of Science 
and Technology.
Competing interests HD and SWH hold positions at the Centre of Innovative 
Ultrasound Solutions at the Norwegian University of Science and Technology, where 
GE Ultrasound is an institutional partner.
Patient consent for publication Not required.
Ethics approval The study protocol was approved by the Regional Committee for 
Health Research Ethics in Norway (identification no. 7179), and by the local ethics 
committee for medical research at Addis Ababa University in Ethiopia. The study 
was conducted in agreement with the second Declaration of Helsinki.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request to the 
authors.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Ståle Wågen Hauge http:// orcid. org/ 0000- 0002- 6585- 5347
Havard Dalen http:// orcid. org/ 0000- 0003- 1192- 3663
REFERENCES
 1 Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, 
and national burden of rheumatic heart disease, 1990-2015. N Engl J 
Med 2017;377:713–22.
 2 Manyemba J, Mayosi BM. Penicillin for secondary prevention of 
rheumatic fever. Cochrane Database Syst Rev 2002;3:CD002227.
 3 Watkins DA, Beaton AZ, Carapetis JR, et al. Rheumatic heart 
disease worldwide: JACC scientific expert panel. J Am Coll Cardiol 
2018;72:1397–416.
 4 Zühlke L, Karthikeyan G, Engel ME, et al. Clinical outcomes in 
3343 children and adults with rheumatic heart disease from 14 
low- and middle- income countries: two- year follow- up of the global 
rheumatic heart disease registry (the REMEDY study). Circulation 
2016;134:1456–66.
 5 Berger M. Natural history of mitral stenosis and echocardiographic 
criteria and pitfalls in selecting patients for balloon valvuloplasty. Adv 
Cardiol 2004;41:87–94.
 6 Carabello BA. Timing of surgery in mitral and aortic stenosis. Cardiol 
Clin 1991;9:229–38.
 7 Zilla P, Bolman RM, Yacoub MH, et al. The Cape Town declaration 
on access to cardiac surgery in the developing world. Eur J 
Cardiothorac Surg 2018;54:407–10.
 8 Kwan GF, Mayosi BM, Mocumbi AO, et al. Endemic cardiovascular 
diseases of the poorest billion. Circulation 2016;133:2561–75.
 9 Mayosi B. The four pillars of rheumatic heart disease control. S Afr 
Med J 2010;100:506.
 10 Remenyi B, ElGuindy A, Smith SC, et al. Valvular aspects of 
rheumatic heart disease. Lancet 2016;387:1335–46.
 11 Vervoort D, Swain JD, Pezzella AT, et al. Cardiac surgery in low- and 
middle- income countries: a state- of- the- art review. Ann Thorac Surg 
2021;111:1394–400.
 12 Carapetis JR. Rheumatic heart disease in developing countries. N 
Engl J Med 2007;357:439–41.
 13 McCallum AH. Natural history of rheumatic fever and rheumatic heart 
disease. ten- year report of a co- operative clinical trial of A.C.T.H, 
cortisone, and aspirin. Br Med J 1965;2:607–13.
 14 Magida MG, Streitfeld FH. The natural history of rheumatic heart 
disease in the third, fourth, and fifth decades of life. Circulation 
1957;16:713–22.
 15 Selzer A, Cohn KE. Natural history of mitral stenosis: a review. 
Circulation 1972;45:878–90.
 16 Zilla P, Williams DF, Bezuidenhout D. TAVR for Patients With 
Rheumatic Heart Disease. J Am Coll Cardiol 2021;77:1714–6.
 17 European Society of cardiology. Rheumatic heart disease seminar.




 18 Mirabel M, Lachaud M, Offredo L, et al. Cardiac surgery in low- 
income settings: 10 years of experience from two countries. Arch 
Cardiovasc Dis 2017;110:82–90.
 19 Swain JD, Sinnott C, Breakey S, et al. Ten- year clinical experience of 
humanitarian cardiothoracic surgery in Rwanda: building a platform 
for ultimate sustainability in a resource- limited setting. J Thorac 
Cardiovasc Surg 2018;155:2541–50.
 20 Scherman J, Manganyi R, Human P, et al. Isolated mechanical aortic 
valve replacement in rheumatic patients in a low- to middle- income 
country. J Thorac Cardiovasc Surg 2019;157:886–93.
 21 Tamirat S, Mazine A, Stevens L- M, et al. Contemporary outcomes 
of aortic and mitral valve surgery for rheumatic heart disease in 
sub- Saharan Africa. J Thorac Cardiovasc Surg 2020. doi:10.1016/j.
jtcvs.2020.02.139. [Epub ahead of print: 25 Apr 2020].
 22 Tibazarwa KB, Volmink JA, Mayosi BM. Incidence of acute rheumatic 
fever in the world: a systematic review of population- based studies. 
Heart 2008;94:1534–40.
 23 Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart 
disease detected by echocardiographic screening. N Engl J Med 
2007;357:470–6.
 24 Parks T, Kado J, Miller AE, et al. Rheumatic heart disease- 
attributable mortality at ages 5-69 years in Fiji: a five- year, National, 
population- based record- linkage cohort study. PLoS Negl Trop Dis 
2015;9:e0004033.
 25 Zühlke LJ, Engel ME, Watkins D, et al. Incidence, prevalence and 
outcome of rheumatic heart disease in South Africa: a systematic 
review of contemporary studies. Int J Cardiol 2015;199:375–83.
 26 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the 
diagnosis and treatment of acute and chronic heart failure. Rev Esp 
Cardiol 2016;69:1167.
 27 EuroSCOREII, 2011. Available: http:// euroscore. pil- media. com/ index. 
php? id= 17& lang= en
 28 Brennan JM, Blair JE, Goonewardena S, et al. Reappraisal of the use 
of inferior vena cava for estimating right atrial pressure. J Am Soc 
Echocardiogr 2007;20:857–61.
 29 Wilkins GT, Weyman AE, Abascal VM, et al. Percutaneous balloon 
dilatation of the mitral valve: an analysis of echocardiographic 
variables related to outcome and the mechanism of dilatation. Br 
Heart J 1988;60:299–308.
 30 Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic 
assessment of valve stenosis: EAE/ASE recommendations for 
clinical practice. Eur J Echocardiogr 2009;10:1–25.
 31 Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines 
for the management of valvular heart disease. Eur Heart J 
2017;38:2739–91.
 32 Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline 
for the management of patients with valvular heart disease: a report 
of the American College of Cardiology/American Heart Association 
Task force on practice guidelines. Circulation 2014;129:e521–643.
 33 Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for 
the management of infective endocarditis: the task force for the 
management of infective endocarditis of the European Society of 
Cardiology (ESC). endorsed by: European Association for Cardio- 
Thoracic Surgery (EACTS), the European Association of Nuclear 
Medicine (EANM). Eur Heart J 2015;36:3075–128.
 34 Casalino R, Tarasoutchi F, Spina G, et al. EuroSCORE models in a 
cohort of patients with valvular heart disease and a high prevalence 
of rheumatic fever submitted to surgical procedures. PLoS One 
2015;10:e0118357.
 35 Rusingiza EK, El- Khatib Z, Hedt- Gauthier B, et al. Outcomes for 
patients with rheumatic heart disease after cardiac surgery followed 







ber 11, 2021 at H






eart: first published as 10.1136/openhrt-2021-001706 on 10 A
ugust 2021. D
ow
nloaded from
 
